Chronic Lymphocytic Leukemia Therapeutics Market in G8 Countries Analyzed in New Report Published at MarketPublishers.com21 Dec 2011 • by Natalie Aster
LONDON – Chronic lymphocytic leukemia (CLL) is still an arena with high unmet need for early diagnosis and limited treatment options in this area. North America was the major contributor to CLL market, accounting for 61.21% of the total sales of CLL drugs last year; whereas Campath was the major drug accounting for 42.32% of the total sales of CLL drugs during the same period. Segmented into two types – childhood and adulthood chronic lymphocytic leukemia (CLL), the market is expected to grow at 13.43% CAGR from 2015 to 2020, and is anticipated to be equally dominated by GA101/RG7159 molecule and Arzerra drug in 2020. Fludara is also highly effective in the treatment of CLL that captured the high market share of the overall CLL market.
New market research report “Chronic Lymphocytic Leukemia Therapeutics Market (2010 – 2020) (Pipeline Assessment & Market Forecast in G8 Countries)” prepared by MarketsandMarkets thoroughly examines the leukemia therapeutics market in G8 countries, analyzing geography, forecasting revenues and trends in the following submarkets – chemotherapy regimens, chemotherapy drugs, pipeline drugs. To contribute to a better understanding of the sector, the study gives detailed insights into major market drivers, challenges, opportunities, and key issues. Furthermore, assessment of the competitive landscape, profiles of leading players alone with their market shares, recent developments and other strategic industry activities can also be found in the review.
The geographies covered in the report include: North America (U.S. and Canada), Europe (U.K., Germany, Italy, France, Spain) and Japan.
Title: Chronic Lymphocytic Leukemia Therapeutics Market (2010 - 2020) (Pipeline Assessment & Market Forecast in G8 Countries)
Published: December, 2011
Price: US$ 4,650
More new research reports by MarketsandMarkets can be found at https://marketpublishers.com/members/marketsnmarkets/info.html